for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Ironwood, Allergan Announce Settlement Resolving Linzess (Linaclotide) Patent Litigation

Jan 6 (Reuters) - Ironwood Pharmaceuticals:

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

* CO, ALLERGAN REACH DEAL WITH SANDOZ RESOLVING LINZESS (LINACLOTIDE) PATENT LITIGATION

* CO, ALLERGAN TO GRANT SANDOZ LICENSE TO MARKET 145 MCG & 290 MCG GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 5, 2030

* HATCH-WAXMAN LITIGATION BETWEEN COS & SANDOZ REGARDING LINZESS PATENTS PENDING IN US DISTRICT COURT FOR DISTRICT OF DELAWARE TO BE DISMISSED

* IRONWOOD PHARMACEUTICALS- COMPANIES WILL SUBMIT SETTLEMENT AGREEMENT TO U.S. FEDERAL TRADE COMMISSION AND U.S. DEPARTMENT OF JUSTICE FOR REVIEW

* PATENT INFRINGEMENT LITIGATION BROUGHT BY COS AGAINST TEVA PHARMACEUTICALS USA REMAIN PENDING

* TRIAL THAT WAS SCHEDULED TO BEGIN ON JAN 7 HAS BEEN POSTPONED TO ENABLE PARTIES TO CONTINUE SETTLEMENT NEGOTIATIONS Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up